Generic Drugs Stock Performance Review -- Ironwood Pharma, Medicines Co., Supernus Pharma, and Pacira Pharma

Monday, June 12, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 12, 2017 /PRNewswire/ -- reviews for today Ironwood Pharmaceuticals Inc. (NASDAQ:

IRWD), The Medicines Co. (NASDAQ: MDCO), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). According to Research and Markets' report, titled "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
2017," the US is the biggest Generic Drugs market in the world. In fact, nearly 80% of the prescriptions written in the US are for generic drugs. These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Ironwood Pharma 

Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s shares declined 0.94%, finishing last Friday's session at $17.83. A total volume of 910,460 shares was traded. Over the last month and the previous three months, the stock has advanced 1.89% and 2.65%, respectively. Furthermore, the Company's shares have gained 16.61% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.68% and 12.61%, respectively. Additionally, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 52.28.

On June 08th, 2017, Ironwood Pharma announced that it will present a corporate update at the Goldman Sachs 38th Annual Global Healthcare Conference on June 15th, 2017, at 1:00 p.m. ET at the Terranea Resort in Rancho Palos Verdes, California. A live webcast of the presentation will be accessible under the Investors section of the Company's website. Your complete research report on IRWD can be retrieved for free at:

Medicines Co. 

On Friday, shares in Parsippany, New Jersey-based The Medicines Co. ended the session 1.64% lower at $39.03. The stock recorded a trading volume of 865,648 shares. The Company's shares have gained 15.00% on an YTD basis. The stock is trading below its 200-day moving average by 6.47%. Moreover, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 30.65. A free report on MDCO is just a click away at:

Supernus Pharma 

Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock dropped 5.36%, to close the day at $38.85. A total volume of 797,108 shares was traded, which was above their three months average volume of 600,830 shares. The Company's shares have surged 21.79% in the last one month, 47.44% over the previous three months, and 53.86% since the start of this year. The stock is trading 15.92% and 46.29% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 62.79.

On June 01st, 2017, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Sign up for your complimentary research report on SUPN at:

Pacira Pharma 

Shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. recorded a trading volume of 621,454 shares. The stock ended at $44.20, slightly down 0.67% from the last trading session. The Company's shares have gained 36.84% on an YTD basis. The stock is trading above its 200-day moving average by 9.49%. Furthermore, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 39.64.

On May 23rd, 2017, Pacira Pharma announced that James Scibetta is resigning as the Company's President to become CEO of an undisclosed, private early-stage oncology company. The Company will allocate Mr. Scibetta's operational oversight responsibilities to the current leadership team, and does not intend to name a successor. Mr. Scibetta will remain with the Company through June 30th, 2017, to ensure a seamless, transition period. Register for free on and download the latest research report on PCRX at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store